Weiner Daniel E
Division of Nephrology, Tufts-New England Medical Center, Boston MA 02111, USA.
J Manag Care Pharm. 2007 Apr;13(3 Suppl):S1-9. doi: 10.18553/jmcp.2007.13.s3.1.
Chronic kidney disease (CKD) is a major public health problem that often goes unrecognized until late-stage disease. In the United States, nearly 20 million people have CKD, and this number is likely to grow as the population ages and the prevalence of diabetes and hypertension rises. With $28 billion currently spent on end-stage renal disease care in the United States and with the rapidly expanding dialysis population, it is essential to actively address this epidemic, both by reducing the number of patients who reach kidney failure and by decreasing morbidity and mortality among those with early-stage CKD.
To review the burden of CKD and its comorbidities on patients, physicians, and payers and discuss the potential benefits to individual patients and society of identifying and treating earlier stages of CKD.
Major steps in dealing with the CKD epidemic are (1) identifying individuals at risk for and with earlier stages of CKD, (2) initiating therapies to slow progression of kidney disease, and (3) treating comorbid conditions associated with CKD, including cardiovascular disease and anemia.
慢性肾脏病(CKD)是一个重大的公共卫生问题,通常在疾病晚期才被发现。在美国,近2000万人患有CKD,随着人口老龄化以及糖尿病和高血压患病率的上升,这一数字可能会增加。美国目前在终末期肾病护理方面花费280亿美元,且透析人群迅速扩大,因此必须积极应对这一流行病,既要减少发展到肾衰竭的患者数量,又要降低早期CKD患者的发病率和死亡率。
回顾CKD及其合并症给患者、医生和支付方带来的负担,并讨论识别和治疗CKD早期阶段对个体患者和社会的潜在益处。
应对CKD流行的主要措施包括:(1)识别有CKD风险和处于CKD早期阶段的个体;(2)启动治疗以减缓肾病进展;(3)治疗与CKD相关的合并症,包括心血管疾病和贫血。